21
cfr
part
442
[
docket
no
.
94n0132
]
antibiotic
drugs
;
cefotetan
and
cefotetan
sodium
injection
<
agency
>
agency
:
food
and
drug
administration
,
hhs
.
<
agency
>
<
action
>
action
:
final
rule
.
<
action
>
<
summary
>
summary
:
the
food
and
drug
administration
(
fda
)
is
amending
the
antibiotic
drug
regulations
to
provide
for
the
inclusion
of
accepted
standards
for
a
new
bulk
form
of
cefotetan
,
cefotetan
,
and
for
its
use
in
a
new
dosage
form
of
cefotetan
sodium
,
cefotetan
sodium
injection
.
the
manufacturer
has
supplied
sufficient
data
and
information
to
establish
its
safety
and
efficacy
.
<
summary
>
<
date
>
dates
:
effective
06/24/1994
;
written
comments
,
notice
of
participation
,
and
requests
for
a
hearing
by
06/24/1994
;
data
,
information
,
and
analyses
to
justify
a
hearing
by
07/25/1994
.
<
date
>
<
address
>
addresses
:
submit
written
comments
to
the
dockets
management
branch
(
hfa305
hfa
,
food
and
drug
administration
,
rm
.
123
,
12420
parklawn
dr
,
rockville
,
md
20857
.
<
address
>
<
further
>
for
further
information
contact
:
peter
a
.
dionne
,
center
for
drug
evaluation
and
research
(
hfd520
hfd
,
food
and
drug
administration
,
5600
fishers
lane
,
rockville
,
md
20857
,
3014430335
.
<
further
>
<
supplem
>
supplementary
information
:
fda
has
evaluated
data
submitted
in
accordance
with
regulations
promulgated
under
section
507
of
the
federal
food
,
drug
,
and
cosmetic
act
(
21
usc
.
357
,
as
amended
,
with
respect
to
a
request
for
approval
of
(
1
)
a
new
bulk
form
of
cefotetan
,
cefotetan
,
and
(
2
)
for
its
use
in
a
new
dosage
form
of
cefotetan
sodium
,
cefotetan
sodium
injection
.
the
agency
has
concluded
that
the
data
supplied
by
the
manufacturer
concerning
this
antibiotic
drug
are
adequate
to
establish
its
safety
and
efficacy
when
used
as
directed
in
the
labeling
and
that
the
regulations
should
be
amended
in
21
cfr
part
442
to
provide
for
the
inclusion
of
accepted
standards
for
this
product
.
environmental
impact
the
agency
has
determined
under
21
cfr
25
24
)
that
this
action
is
of
a
type
that
does
not
individually
or
cumulatively
have
a
significant
effect
on
the
human
environment
.
therefore
,
neither
an
environmental
assessment
nor
an
environmental
impact
statement
is
required
.
submitting
comments
and
filing
objections
this
final
rule
announces
standards
that
fda
has
accepted
in
a
request
for
approval
of
an
antibiotic
drug
.
because
this
final
rule
is
not
controversial
and
because
,
when
effective
,
it
provides
notice
of
accepted
standards
,
fda
finds
that
notice
and
comment
procedure
is
unnecessary
and
not
in
the
public
interest
.
this
final
rule
,
therefore
,
is
effective
06/24/1994
.
however
,
interested
persons
may
,
on
or
before
06/24/1994
,
submit
written
comments
to
the
dockets
management
branch
(
address
above
.
two
copies
of
any
comments
are
to
be
submitted
,
except
that
individuals
may
submit
one
copy
.
comments
are
to
be
identified
with
the
docket
number
found
in
brackets
in
the
heading
of
this
document
.
received
comments
may
be
seen
in
the
dockets
management
branch
between
9
am
.
and
4
pm
,
monday
through
friday
.
any
person
who
will
be
adversely
affected
by
this
final
rule
may
file
objections
to
it
and
request
a
hearing
.
reasonable
grounds
for
the
hearing
must
be
shown
.
any
person
who
decides
to
seek
a
hearing
must
file
(
1
)
on
or
before
06/24/1994
,
a
written
notice
of
participation
and
request
for
a
hearing
,
and
(
2
)
on
or
before
07/25/1994
,
the
data
,
information
,
and
analyses
on
which
the
person
relies
to
justify
a
hearing
,
as
specified
in
21
cfr
314
300
.
a
request
for
a
hearing
may
not
rest
upon
mere
allegations
or
denials
,
but
must
set
forth
specific
facts
showing
that
there
is
a
genuine
and
substantial
issue
of
fact
that
requires
a
hearing
.
if
it
conclusively
appears
from
the
face
of
the
data
,
information
,
and
factual
analyses
in
the
request
for
a
hearing
that
no
genuine
and
substantial
issue
of
fact
precludes
the
action
taken
by
this
order
,
or
if
a
request
for
a
hearing
is
not
made
in
the
required
format
or
with
the
required
analyses
,
the
commissioner
of
food
and
drugs
will
enter
summary
judgment
against
the
persons
)
who
requests
)
the
hearing
,
making
findings
and
conclusions
and
denying
a
hearing
.
all
submissions
must
be
filed
in
three
copies
,
identified
with
the
docket
number
appearing
in
the
heading
of
this
document
and
filed
with
the
dockets
management
branch
.
the
procedures
and
requirements
governing
this
order
,
a
notice
of
participation
and
request
for
a
hearing
,
a
submission
of
data
,
information
,
and
analyses
to
justify
a
hearing
,
other
comments
,
and
grant
or
denial
of
a
hearing
are
contained
in
21
cfr
314
300
.
all
submissions
under
this
order
,
except
for
data
and
information
prohibited
from
public
disclosure
under
21
usc
.
331j
)
or
18
usc
.
1905
,
may
be
seen
in
the
dockets
management
branch
(
address
above
)
between
9
am
.
and
4
pm
,
monday
through
friday
.
list
of
subjects
in
21
cfr
part
442
antibiotics
.
therefore
,
under
the
federal
food
,
drug
,
and
cosmetic
act
and
under
authority
delegated
to
the
commissioner
of
food
and
drugs
,
21
cfr
part
442
is
amended
as
follows
:
part
442cepha
antibiotic
drugs
1
.
the
authority
citation
for
21
cfr
part
442
continues
to
read
as
follows
:
authority
:
sec
.
507
of
the
federal
food
,
drug
,
and
cosmetic
act
(
21
usc
.
357
.
2
.
new
§
442
52
is
added
to
subpart
a
to
read
as
follows
:
§
442
52
cefotetan
.
(
a
)
requirements
for
certification
_
1
)
standards
of
identity
,
strength
,
quality
,
and
purity
.
.
cefotetan
is
(
6
,
7
)
42carboxy7methoxy31methyl1
carboxy
-
tetrazol5ylthiomethyl8oxo5thia1azabicyclo420oct2ene7ylcarbamoyl13dithietane
tetrazol
-
2
,
-
malonamic
acid
.
it
is
so
purified
and
dried
that
:
(
i
)
its
potency
is
not
less
than
950
micrograms
and
not
more
than
1030
micrograms
of
cefotetan
activity
per
milligram
on
the
anhydrous
basis
.
(
ii
)
its
moisture
content
is
not
more
than
25
percent
.
(
iii
)
it
gives
a
positive
identity
test
for
cefotetan
.
(
2
)
labeling
.
.
it
shall
be
labeled
in
accordance
with
the
requirements
of
§
4325
of
this
chapter
.
(
3
)
requests
for
certification
;
samples
.
.
in
addition
to
complying
with
the
requirements
of
§
4311
of
this
chapter
,
each
such
request
shall
contain
:
(
i
)
results
of
tests
and
assays
on
the
batch
for
potency
,
moisture
,
and
identity
.
(
ii
)
samples
,
if
required
by
the
director
,
center
for
drug
evaluation
and
research
:
10
packages
each
containing
approximately
500
milligrams
.
(
b
)
tests
and
methods
of
assay
_
1
)
potency
.
.
proceed
as
directed
in
§
436
216
of
this
chapter
,
except
use
the
resolution
test
solution
to
determine
resolution
in
lieu
of
the
working
standard
solution
.
perform
the
assay
at
ambient
temperature
,
using
an
ultraviolet
detection
system
operating
at
a
wavelength
of
254
nanometers
,
a
column
packed
with
microparticulate
(
3
to
10
micrometers
in
diameter
)
reversed
phase
packing
material
such
as
octadecyl
hydrocarbon
bonded
silicas
,
a
flow
rate
not
exceeding
2
milliliters
per
minute
,
and
a
known
injection
volume
of
between
10
and
20
microliters
.
reagents
,
working
standard
solution
,
sample
solution
,
resolution
test
solution
,
system
suitability
requirements
,
and
calculations
are
as
follows
:
(
i
)
reagents
_
a
)
diluting
solution
.
.
mix
watermethanolacetonitrile
(
9055
.
(
b
)
mobile
phase
.
.
mix
01
phosphoric
acidglacial
acetic
acidmethanolacetonitrile
(
1700100105105
.
filter
through
a
suitable
filter
capable
of
removing
particulate
matter
greater
than
05
micron
in
diameter
.
degas
the
mobile
phase
just
prior
to
its
introduction
into
the
chromatograph
.
(
ii
)
preparation
of
working
standard
,
sample
,
and
resolution
test
solutions
_
a
)
working
standard
solution
.
.
accurately
weigh
approximately
50
milligrams
of
the
cefotetan
working
standard
into
a
250milliliter
milliliter
volumetric
flask
containing
125
milliliters
of
methanol
.
swirl
the
flask
for
several
minutes
,
then
add
125
milliliters
of
acetonitrile
.
swirl
the
flask
until
the
cefotetan
is
dissolved
.
dilute
to
volume
with
water
to
obtain
a
solution
containing
approximately
200
micrograms
of
cefotetan
per
milliliter
.
mix
well
.
protect
the
working
standard
solution
from
light
.
(
b
)
sample
solution
.
.
dissolve
an
accurately
weighed
portion
of
the
sample
with
sufficient
diluting
solution
described
in
paragraph
(
b1ia
)
of
this
section
to
obtain
a
concentration
of
approximately
200
micrograms
of
cefotetan
per
milliliter
.
(
c
)
resolution
test
solution
.
.
place
10
milliliters
of
the
working
standard
solution
in
a
stoppered
flask
containing
a
few
milligrams
of
magnesium
carbonate
.
close
the
flask
and
sonicate
for
10
minutes
.
if
the
solution
is
not
slightly
turbid
,
add
more
magnesium
carbonate
and
repeat
sonication
.
filter
the
turbid
solution
through
a
05micron
micron
filter
and
use
within
2
hours
.
as
this
solution
stands
,
the
tautomer
concentration
increases
.
(
iii
)
system
suitability
requirements
_
a
)
tailing
factor
.
.
the
tailing
factor
(
(
)
)
is
satisfactory
if
it
is
not
more
than
13
at
10
percent
of
peak
height
in
lieu
of
5
percent
of
peak
height
.
(
b
)
efficiency
of
the
column
.
.
the
efficiency
of
the
column
(
(
)
)
is
satisfactory
if
it
is
greater
than
1500
theoretical
plates
.
(
c
)
resolution
.
.
the
resolution
(
(
)
)
between
the
peak
for
cefotetan
and
its
tautomer
is
satisfactory
if
it
is
not
less
than
2
.
(
d
)
coefficient
of
variation
.
.
the
coefficient
of
variation
(
(
in
percent
)
of
five
replicate
injections
is
satisfactory
if
it
is
not
more
than
2
percent
.
if
the
system
suitability
requirements
have
been
met
,
then
proceed
as
described
in
§
436
216
)
of
this
chapter
.
alternate
chromatographic
conditions
are
acceptable
provided
comparable
system
suitability
requirements
are
met
.
however
,
the
sample
preparation
described
in
paragraph
(
b1iib
)
of
this
section
should
not
be
changed
.
(
iv
)
calculation
.
.
calculate
the
micrograms
of
cefotetan
per
milligram
of
sample
as
follows
:
<
table
>
1micrograms
of
cefotetan
per
milligram
1
=
x
x
100
x
x
(
100
-
<
table
>
where
:
=
=
area
of
the
cefotetan
peak
in
the
chromatogram
of
the
sample
(
at
a
retention
time
equal
to
that
observed
for
the
standard
;
=
=
area
of
the
cefotetan
peak
in
the
chromatogram
of
the
cefotetan
working
standard
;
=
=
cefotetan
activity
in
the
cefotetan
working
standard
solution
in
micrograms
per
milliliter
;
=
=
milligrams
of
sample
per
milliliter
of
sample
solution
;
and
=
=
percent
moisture
content
of
the
sample
.
(
2
)
moisture
.
.
proceed
as
directed
in
§
436
201
of
this
chapter
.
(
3
)
identity
.
.
proceed
as
directed
in
§
436
211
of
this
chapter
using
a
mineral
oil
mull
prepared
as
described
in
§
436
211
.
§
442
253a
[
redesignated
from
§
442
253
]
3
.
section
442
253
is
redesignated
as
§
442
253a
and
new
§
442
253
and
442
253b
are
added
to
subpart
c
to
read
as
follows
:
§
442
253
cefotetan
injectable
dosage
forms
.
§
442
253b
cefotetan
sodium
injection
.
(
a
)
requirements
for
certification
_
1
)
standards
of
identity
,
strength
,
quality
,
and
purity
.
.
cefotetan
sodium
injection
is
a
frozen
,
aqueous
,
isoosmotic
iso
osmotic
solution
of
cefotetan
and
sodium
bicarbonate
.
it
contains
one
or
more
suitable
and
harmless
buffer
substances
and
a
tonicity
adjusting
agent
.
each
milliliter
contains
cefotetan
disodium
equivalent
to
20
milligrams
or
40
milligrams
of
cefotetan
per
milliliter
.
its
cefotetan
content
is
satisfactory
if
it
is
not
less
than
90
percent
and
not
more
than
120
percent
of
the
number
of
milligrams
of
cefotetan
that
it
is
represented
to
contain
.
it
is
sterile
.
it
contains
not
more
than
0
17
endotoxin
units
per
milligram
of
cefotetan
.
its
ph
is
not
less
than
4
and
not
more
than
65
.
it
passes
the
identity
test
.
the
cefotetan
used
conforms
to
the
standards
prescribed
by
§
442
52
.
(
2
)
labeling
.
.
it
shall
be
labeled
in
accordance
with
the
requirements
of
§
4325
of
this
chapter
.
(
3
)
requests
for
certification
;
samples
.
.
in
addition
to
complying
with
the
requirements
of
§
4311
of
this
chapter
,
each
such
request
shall
contain
:
(
i
)
results
of
tests
and
assays
on
:
(
a
)
the
cefotetan
used
in
making
the
batch
for
cefotetan
potency
,
moisture
,
and
identity
.
(
b
)
the
batch
for
cefotetan
potency
,
sterility
,
bacterial
endotoxins
,
ph
,
and
identity
.
(
ii
)
samples
,
if
required
by
the
director
,
center
for
drug
evaluation
and
research
:
(
a
)
the
cefotetan
used
in
making
the
batch
:
10
packages
,
each
containing
approximately
500
milligrams
.
(
b
)
the
batch
:
)
)
for
all
tests
except
sterility
:
a
minimum
of
12
immediate
containers
.
)
)
for
sterility
testing
:
20
immediate
containers
,
collected
at
regular
intervals
throughout
each
filling
operation
.
(
b
)
tests
and
methods
of
assay
.
.
thaw
the
sample
as
directed
in
the
labeling
.
the
sample
solution
used
for
testing
must
be
at
room
temperature
.
(
1
)
cefotetan
potency
.
.
proceed
as
directed
in
§
442
52
,
except
prepare
the
sample
solution
and
calculate
the
cefotetan
content
as
follows
:
(
i
)
preparation
of
sample
solution
.
.
using
a
suitable
hypodermic
needle
and
syringe
,
remove
an
accurately
measured
portion
from
each
container
immediately
after
thawing
and
reaching
room
temperature
and
dilute
with
mobile
phase
to
obtain
a
solution
containing
200
micrograms
of
cefotetan
per
milliliter
(
estimated
.
prepare
the
sample
solution
just
prior
to
its
introduction
into
the
chromatograph
.
(
ii
)
calculation
.
.
calculate
the
milligrams
of
cefotetan
per
milliliter
of
sample
as
follows
:
<
table
>
1micrograms
of
cefotetan
per
milligram
1
=
x
x
100
x
x
(
100
-
<
table
>
where
:
=
=
area
of
the
cefotetan
peak
in
the
chromatogram
of
the
sample
(
at
a
retention
time
equal
to
that
observed
for
the
standard
;
=
=
area
of
the
cefotetan
peak
in
the
chromatogram
of
the
cefotetan
working
standard
;
=
=
cefotetan
activity
in
the
cefotetan
working
standard
solution
in
micrograms
per
milliliter
;
=
=
milligrams
of
sample
per
milliliter
of
sample
solution
;
and
=
=
percent
moisture
content
of
the
sample
.
(
2
)
sterility
.
.
proceed
as
directed
in
§
436
20
of
this
chapter
,
using
the
method
described
in
paragraph
(
e1
)
of
that
section
.
(
3
)
bacterial
endotoxins
.
.
proceed
as
directed
in
the
us
.
pharmacopeia
bacterial
endotoxins
test
.
(
4
)
ph
.
.
proceed
as
directed
in
§
436
202
of
this
chapter
,
using
the
undiluted
solution
.
(
5
)
identity
.
.
the
highperformance
high
performance
liquid
chromatogram
of
the
sample
determined
as
directed
in
paragraph
(
b1
)
of
this
section
compares
qualitatively
to
that
of
the
cefotetan
working
standard
.
dated
:
05/17/1994
.
<
supplem
>
<
signer
>
gayle
r
.
dolecek
,
<
signer
>
<
signjob
>
acting
director
,
office
of
compliance
,
center
for
drug
evaluation
and
research
.
<
signjob
>
<
frfiling
>
[
fr
doc
.
9412667
filed
05/24/1994
;
845
am
]
<
frfiling
>
<
billing
>
billing
code
416001f
<
billing
>
<
text
>
